XML 21 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Millions
Total
Common Stock and Additional Paid-in Capital [Member]
Parent [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Class A Common Stock (Shares) [Member]
Class B Common Stock (Shares) [Member]
Convertible Preferred Stock
Total CME Group Shareholders' Equity, beginning at Dec. 31, 2021   $ 22,193.9 $ 27,399.3 $ 5,151.9 $ 53.5      
Beginning Balance (in shares) at Dec. 31, 2021           358,599 3 4,584
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income attributable to CME Group     2,691.0 2,691.0        
Net income $ 2,691.0              
Other comprehensive income/(loss) (186.8)   (186.8)   (186.8)      
Dividends, Cash     (3,096.1) (3,096.1)        
Exercise of stock options   0.1 0.1          
Exercise of stock options (in shares)           1    
Vesting of issued restricted Class A common stock, shares           269    
Vesting of issued restricted Class A common stock, value   (24.8) (24.8)          
Shares issued to Board of Directors (in shares)           19    
Stock Issued to Board of Directors, Value, Issued for Services   4.0 4.0          
Shares issued under Employee Stock Purchase Plan (in shares)           41    
Shares issued under Employee Stock Purchase Plan   7.7 7.7          
Stock-based compensation   84.3 84.3          
Total CME Group Shareholders' Equity, ending at Dec. 31, 2022   22,265.2 26,878.7 4,746.8 (133.3)      
Ending Balance (in shares) at Dec. 31, 2022           358,929 3 4,584
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income attributable to CME Group 3,226.2   3,226.2          
Net income 3,226.2              
Other comprehensive income/(loss) 77.7   77.7   77.7      
Dividends, Cash     (3,517.8) (3,517.8)        
Vesting of issued restricted Class A common stock, shares           241    
Vesting of issued restricted Class A common stock, value   (21.4) (21.4)          
Shares issued to Board of Directors (in shares)           20    
Stock Issued to Board of Directors, Value, Issued for Services   3.6 3.6          
Shares issued under Employee Stock Purchase Plan (in shares)           41    
Shares issued under Employee Stock Purchase Plan   8.0 8.0          
Stock-based compensation   82.9 82.9          
Total CME Group Shareholders' Equity, ending at Dec. 31, 2023 26,737.9 22,338.3 26,737.9 4,455.2 (55.6)      
Ending Balance (in shares) at Dec. 31, 2023           359,231 3 4,584
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income attributable to CME Group 3,525.8   3,525.8          
Net income 3,525.8              
Other comprehensive income/(loss) (49.9)   (49.9)   (49.9)      
Dividends, Cash     (3,795.2) (3,795.2)        
Vesting of issued restricted Class A common stock, shares           315    
Vesting of issued restricted Class A common stock, value   (33.0) (33.0)          
Shares issued to Board of Directors (in shares)           19    
Stock Issued to Board of Directors, Value, Issued for Services   3.7 3.7          
Shares issued under Employee Stock Purchase Plan (in shares)           37    
Shares issued under Employee Stock Purchase Plan   8.1 8.1          
Stock-based compensation   89.5 89.5          
Total CME Group Shareholders' Equity, ending at Dec. 31, 2024 $ 26,486.9 $ 22,406.6 $ 26,486.9 $ 4,185.8 $ (105.5)      
Ending Balance (in shares) at Dec. 31, 2024           359,602 3 4,584